Literature DB >> 18331824

Short interfering RNA directed against TWIST, a novel zinc finger transcription factor, increases A549 cell sensitivity to cisplatin via MAPK/mitochondrial pathway.

Wen-Lei Zhuo1, Yan Wang, Xian-Lu Zhuo, Yun-Song Zhang, Zheng-Tang Chen.   

Abstract

Previous reports have implicated epithelial-mesenchymal transition (EMT) as a major cause of cancer. TWIST, a novel zinc finger transcription factor, was suggested to be an important inducer of EMT and therefore be involved in different phases of tumorigenicity. However, whether TWIST suppression could increase chemosensitivity of cancer cells to chemotherapeutic agent remains unclear. In the present study, we utilized RNA interference to knockdown TWIST expression in A549 cells and further assessed the cell viability and apoptosis as well as possible MAPKs and mitochondrial pathways. The data showed that TWIST depletion significantly sensitized A549 cells to cisplatin by inducing activation of JNK/mitochondrial pathway but not ERK and p-38 pathways, suggesting critical roles of TWIST in A549 cell chemoresistance to cisplatin and raising the possibility of TWIST depletion as a promising approach to lung cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18331824     DOI: 10.1016/j.bbrc.2008.02.143

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  40 in total

Review 1.  Chemotherapy and signaling: How can targeted therapies supercharge cytotoxic agents?

Authors:  Tetyana V Bagnyukova; Ilya G Serebriiskii; Yan Zhou; Elizabeth A Hopper-Borge; Erica A Golemis; Igor Astsaturov
Journal:  Cancer Biol Ther       Date:  2010-11-01       Impact factor: 4.742

2.  miR-495 promotes the chemoresistance of SCLC through the epithelial-mesenchymal transition via Etk/BMX.

Authors:  Ting Wei; Weiliang Zhu; Shun Fang; Xiangpin Zeng; Jie Huang; Jie Yang; Jian Zhang; Linlang Guo
Journal:  Am J Cancer Res       Date:  2017-03-01       Impact factor: 6.166

Review 3.  Therapeutic Targeting of Epithelial Plasticity Programs: Focus on the Epithelial-Mesenchymal Transition.

Authors:  Reem Malek; Hailun Wang; Kekoa Taparra; Phuoc T Tran
Journal:  Cells Tissues Organs       Date:  2017-02-20       Impact factor: 2.481

4.  Nanoparticle-mediated down-regulation of TWIST increases radiosensitivity of nasopharyngeal carcinoma cells via ERK pathway.

Authors:  Xianlu Zhuo; Aoshuang Chang; Chuang Huang; Li Yang; Houyu Zhao; Yongzhong Wu; Qi Zhou
Journal:  Am J Cancer Res       Date:  2015-03-15       Impact factor: 6.166

Review 5.  Epithelial-to-mesenchymal transitions and circulating tumor cells.

Authors:  Arnaud Bonnomet; Anne Brysse; Anthony Tachsidis; Mark Waltham; Erik W Thompson; Myriam Polette; Christine Gilles
Journal:  J Mammary Gland Biol Neoplasia       Date:  2010-05-07       Impact factor: 2.673

6.  Epithelial mesenchymal transition and lung cancer.

Authors:  Dakai Xiao; Jianxing He
Journal:  J Thorac Dis       Date:  2010-09       Impact factor: 2.895

7.  Honokiol inhibits epithelial-mesenchymal transition in breast cancer cells by targeting signal transducer and activator of transcription 3/Zeb1/E-cadherin axis.

Authors:  Dimiter B Avtanski; Arumugam Nagalingam; Michael Y Bonner; Jack L Arbiser; Neeraj K Saxena; Dipali Sharma
Journal:  Mol Oncol       Date:  2014-01-15       Impact factor: 6.603

8.  PKCalpha-induced drug resistance in pancreatic cancer cells is associated with transforming growth factor-beta1.

Authors:  Ying Chen; Guanzhen Yu; Danghui Yu; Minghua Zhu
Journal:  J Exp Clin Cancer Res       Date:  2010-08-05

9.  Cellular responses to Cisplatin-induced DNA damage.

Authors:  Alakananda Basu; Soumya Krishnamurthy
Journal:  J Nucleic Acids       Date:  2010-08-08

Review 10.  The biological and clinical importance of epithelial-mesenchymal transition in circulating tumor cells.

Authors:  Huiying Liu; Xiaofeng Zhang; Jun Li; Bin Sun; Haihua Qian; Zhengfeng Yin
Journal:  J Cancer Res Clin Oncol       Date:  2014-06-26       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.